JPWO2019142147A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019142147A5
JPWO2019142147A5 JP2020540253A JP2020540253A JPWO2019142147A5 JP WO2019142147 A5 JPWO2019142147 A5 JP WO2019142147A5 JP 2020540253 A JP2020540253 A JP 2020540253A JP 2020540253 A JP2020540253 A JP 2020540253A JP WO2019142147 A5 JPWO2019142147 A5 JP WO2019142147A5
Authority
JP
Japan
Prior art keywords
antibody
optionally substituted
antigen
binding fragment
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511333A5 (https=
JP2021511333A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050446 external-priority patent/WO2019142147A2/en
Publication of JP2021511333A publication Critical patent/JP2021511333A/ja
Publication of JPWO2019142147A5 publication Critical patent/JPWO2019142147A5/ja
Publication of JP2021511333A5 publication Critical patent/JP2021511333A5/ja
Pending legal-status Critical Current

Links

JP2020540253A 2018-01-18 2019-01-18 Ｃｄ１３４＋細胞の枯渇のための組成物および方法 Pending JP2021511333A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619106P 2018-01-18 2018-01-18
US62/619,106 2018-01-18
PCT/IB2019/050446 WO2019142147A2 (en) 2018-01-18 2019-01-18 Compositions and methods for the depletion of cd134+ cells

Publications (3)

Publication Number Publication Date
JP2021511333A JP2021511333A (ja) 2021-05-06
JPWO2019142147A5 true JPWO2019142147A5 (https=) 2022-02-24
JP2021511333A5 JP2021511333A5 (https=) 2022-02-24

Family

ID=67300964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540253A Pending JP2021511333A (ja) 2018-01-18 2019-01-18 Ｃｄ１３４＋細胞の枯渇のための組成物および方法

Country Status (5)

Country Link
US (1) US20210101990A1 (https=)
EP (1) EP3740233A4 (https=)
JP (1) JP2021511333A (https=)
CN (1) CN111867621A (https=)
WO (1) WO2019142147A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732807A (zh) * 2022-03-27 2022-07-12 苏州大学 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
EP2068925A4 (en) * 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
WO2010008726A1 (en) * 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
EP2497499A1 (en) * 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
RS58367B1 (sr) * 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
MX2017003123A (es) * 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
US9434785B1 (en) * 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
WO2015151079A2 (en) * 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates

Similar Documents

Publication Publication Date Title
WO2023078273A1 (en) Specific conjugation for an antibody-drug conjugate
US20250064954A1 (en) Steroids and antibody-conjugates thereof
US11767294B2 (en) Conjugates of cell binding molecules with cytotoxic agents
JP2020506176A5 (https=)
ES2701076T3 (es) Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
US10836796B2 (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
CA3129419C (en) Antibody drug conjugate loaded with binary toxins and its application
KR100426113B1 (ko) 티(t)-세포항원,및티(t)-세포매개증상의진단및치료에있어서의이의용도
CA2991384A1 (en) Bridge linkers for conjugation of a cell-binding molecule
AU2015242213A1 (en) Bridge linkers for conjugation of cell-binding molecules
RU2723651C2 (ru) Цитотоксические и антимитотические соединения и способы их применения
BR112019012483A2 (pt) conjugados de fármaco de anticorpo para ablar células-tronco hematopoiéticas
CN106414465A (zh) 带电荷链接体及其在共轭反应上的应用
CN112826940A (zh) 细胞毒素分子同细胞结合受体分子的共轭体
JPWO2019142147A5 (https=)
JP2021511333A5 (https=)
ES2936075T3 (es) Activador de células T reguladoras, y uso del mismo
Choi et al. Selective Depletion of ABO-Responsive B Cells by T-Cell-Engaging Bispecific Antibody Conjugates for ABOi Transplantation
WO2021174021A1 (en) Tunable extended release hydrogels
JPWO2020247670A5 (https=)
JPWO2019173780A5 (https=)
JPWO2021168128A5 (https=)
US20230019107A1 (en) Reversibly inhibited binding molecules
Jensen-Jarolim et al. Mimotopes for Active Immunotherapy of Tumors: Allergooncology
Iwai et al. Gene Expression Analysis by Microarray Following Anti-CD3 Antibody Therapy of NOD Mice